Skip to main content

Table 2 Gas exchange and level of ventilatory support within 24 h of commencement of IMV in patients who received or did not receive neuromuscular blocking agents (NMBAs)

From: Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

 

Unmatched cohort

(N = 1953)

Propensity score-matched cohort (N = 420)

Parameter

Control

(N = 1711)

NMBA treatment

(N = 242)

Control

(N = 210)

NMBA treatment

(N = 210)

pH mean (SD)

7.4 (0.1)

7.3 (0.1)

7.3 (0.1)

7.3 (0.1)

FiO2 (mmHg) mean (SD)

76.1 (21.9)

77.3 (21.9)

81.0 (20.8)

77.5 (22.0)

PaO2/FiO2 (mmHg) mean (SD)

98.1 (31.1)

88.5 (29.3)

86.0 (30.7)

88.6 (29.7)

PaCO2 (mmHg) mean (SD)

48.7 (13.5)

50.9 (13.9)

48.0 (15.5)

51.0 (13.7)

Tidal volume (ml/PBW) mean (SD)

7.1 (1.4)

6.9 (1.4)

7.4 (1.6)

6.8 (1.4)

Respiratory system compliance (mL/cmH2O) mean (SD)

33.8 (11.9)

32.9 (12.7)

33.9 (12.2)

32.5 (12.6)

Plateau pressure (cmH2O) mean (SD)

25.4 (5.7)

26.1 (5.1)

25.0 (5.9)

26.2 (5.0)

Driving pressure (cmH2O) mean (SD)

22.8 (7.4)

22.1 (7.6)

22.4 (8.6)

22.7 (7.5)

Respiratory rate (breaths/min) mean (SD)

23.8 (7.0)

24.5 (7.1)

24.7 (7.4)

24.8 (7.3)

PEEP level (cmH2O) mean (SD)

12.0 (3.0)

12.8 (3.3)

11.9 (3.1)

12.8 (3.3)

Heart rate (beats/min) mean (SD)

89.1 (27.4)

93.9 (29.0)

90.9 (30.5)

95.5 (28.4)

Mean arterial pressure (mmHg) mean (SD)

80.9 (19.8)

77.3 (21.6)

80.2 (20.2)

76.7 (21.7)

  1. NMBA treatment was defined as at least 2 days of continuous use of NMBAs or up to 3 days, within 48 h from commencement of IMV
  2. IMV, invasive mechanical ventilation; FiO2, inspiratory fraction of oxygen; PaO2/FiO2, ratio between arterial partial pressure of oxygen and inspiratory fraction of oxygen; PaCO2, arterial partial pressure of carbon dioxide; PBW, predicted body weight; PEEP, positive end-expiratory pressure